Product Overview
Generic name: Metformin hydrochloride sustained-release tablets
English name: Metformin Hydrochloride Extended-release Tablets
Product name: Lilo
Ingredients: The main ingredient of this product is metformin hydrochloride.
Properties: This product is white to off-white tablets or film-coated tablets, which appear white or off-white after removing the coating.
Functions and indications: Suitable for patients with type 2 diabetes who cannot be well controlled with diet and exercise therapy alone. This product can be used alone or in combination with sulfonylureas or insulin.
Specification: 0.5g*30pcs/box
Usage and dosage: Orally, take it with or after meals. The initial dosage is usually once a day, 1 tablet (500mg) at a time, and taken at dinner. The dosage is adjusted according to blood sugar and urine sugar. The maximum daily dose does not exceed 4 tablets (2000mg). If once a day, 4 tablets (2000mg) each time cannot achieve satisfactory results, it can be changed to 2 tablets (1000mg) twice a day.
Adverse reactions: Some patients have gastrointestinal discomfort after oral administration of this product, such as nausea, vomiting, abdominal pain, diarrhea, constipation, abdominal distension, indigestion, heartburn, dizziness, headache, flu-like symptoms, abnormal taste, muscle pain, Low blood pressure, palpitations, flushing, chills, chest discomfort, rash, fatigue, fatigue, etc.
Contraindications: Type 2 diabetes with ketoacidosis, liver and kidney insufficiency, heart failure, acute myocardial infarction, severe infection and trauma, major surgery, clinical hypotension and hypoxia, and past history of lactic acidosis, And those who are allergic to this product are prohibited.
Note: 1. In patients who use metformin, lactic acidosis may occur due to the accumulation of metformin. This is a rare and serious metabolic complication. Once it occurs, it will lead to life-threatening. Therefore, it is necessary to take this product Patients should be monitored for renal function and administered with the lowest effective dose as the standard to significantly reduce the risk of lactic acidosis.
2 This product is forbidden to be chewed orally. It should be swallowed whole and taken during or after meals.
3 When patients need to conduct radioactivity studies and use intravenous iodinated contrast agents, patients should temporarily stop taking this product, because this may cause acute renal function changes.
Drug interactions: 1 Combined with insulin, the blood sugar lowering effect is strengthened, and the dosage should be adjusted.
2 This product can strengthen the anticoagulant effect of anticoagulants (such as warfarin, etc.), which can cause bleeding tendency.
3 Cimetidine can increase the bioavailability of this product and reduce renal clearance, so the dose of this product should be reduced.
4 Furosemide increases the concentration of metformin in serum and whole blood, but does not change the renal clearance of metformin.
5 Nifedipine can increase the absorption of metformin and increase the excretion in urine, but it does not affect Tmax and half-life.
Pharmacology and Toxicology: This product is a hypoglycemic agent, which can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes, and can reduce HbAlc by 1% to 2%. The mechanism of lowering blood sugar is:
1 Increase the sensitivity of surrounding tissues to insulin and increase insulin-mediated glucose utilization.
2 Increase the utilization of glucose by non-insulin-dependent tissues, such as brain, blood cells, renal medulla, intestine, skin, etc.
3 Inhibit liver gluconeogenesis and reduce liver glycogen output.
4 Inhibit glucose uptake by intestinal wall cells.
Unlike insulin, this product has no effect on promoting fat synthesis and has no obvious blood sugar lowering effect on normal people. Generally, it does not cause hypoglycemia when used alone for type 2 diabetes.
Storage: Keep in a closed, cool and dry place.
Packaging: Aluminum-plastic blister packaging, 30 pieces/box.
Validity period: 24 months
Approval number: National Medicine Zhunzi H20052118
Company Name: Shandong Mingren Furuida Pharmaceutical Co., Ltd.
